Skip to content

Alveolar bone augmentation technology based on 3D printed bioglass scaffolds

Alveolar bone augmentation technology based on 3D printed bioglass scaffolds

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400088689
Enrollment
Unknown
Registered
2024-08-23
Start date
2024-08-31
Completion date
Unknown
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alveolar bone defect

Interventions

Control group: Autogenous bone ring:During the operation, bone rings were taken from the chin, palate or posterior region of the molar. After the affected area was trimmed, the bone rings were transpl
Experimental group: 3D printed bioglass scaffold:After surgical incision, the bone defect was repaired, the 3D printed bioglass scaffold was implanted into the defect, and the titanium nail was implan

Sponsors

Stomatological Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-70 years old (including 18 and 70 years old), gender is not limited; (2) For patients with alveolar bone defects, the absence of teeth in the missing area was at least 3 months; (3) Patients can tolerate 3D printed bioglass scaffold and implant implantation surgery; (4) Patients voluntarily participate in the trial and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) full mouth edentulous jaw; (2) The patient has a blood disease; (3) severe kidney and/or liver disease; Congenital or acquired immunodeficiency; (4) Patients who are receiving radiotherapy or chemotherapy at the time of initial diagnosis; (5) head and neck tumors; (6) Oral mucosal diseases; (7) pregnant and intended pregnant women of childbearing age and breastfeeding women; A male patient whose spouse intends to become pregnant; (8) Poor oral hygiene and poor patient compliance; (9) Tobacco abuse (> 20 cigarettes per day) or alcohol abuse (> 40mL of alcohol per day); (10) Patients with poorly controlled diabetes (fasting blood glucose > 6.8mmol/L) and poorly controlled hypertension (systolic blood pressure =160mmHg and/or diastolic blood pressure =100mmHg); (11) Have a history of bisphosphonate therapy and have stopped for less than 3 months or have metabolic bone disease; (12) Patients with acute periapical inflammation, progressive periodontal disease, refractory periodontitis history, infection, etc.; (13) Patients with other systemic diseases in the whole body, resulting in patients who cannot receive implant treatment; (14) Other patients determined by the investigator to be unsuitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Alveolar Bone Width;Alveolar Bone Height;Alveolar Bone Density;

Secondary

MeasureTime frame
Soft tissue healing status;recipient region Infection;

Countries

China

Contacts

Public ContactChen Tao

Stomatological Hospital of Chongqing Medical University

chentao1985@hospital.cqmu.edu.cn+86 182 2502 9529

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026